FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sherman Matthew L		 2. Issuer Name and Ticker or Trading Symbol

Deciphera Pharmaceuticals, Inc. [ DCPH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP & Chief Medical Officer
(Last)          (First)          (Middle)

C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/15/2019
(Street)

WALTHAM, MA 02451
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/15/2019    A(1)    35000  A $0.00  35000  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $34.43  10/15/2019    A     150000       (2) 10/14/2029  Common Stock  150000  $0.00  150000  D   

Explanation of Responses:
(1)  The reporting person was awarded 35,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in four (4) equal annual installments beginning on October 1, 2020, subject to the reporting person's continuous service with the Company through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
(2)  This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sherman Matthew L
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM, MA 02451

EVP & Chief Medical Officer

Signatures
/s/ Jeffrey M. Held, Attorney-in-Fact 10/17/2019
**Signature of Reporting Person Date


Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Deciphera Pharmaceuticals Charts.
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Deciphera Pharmaceuticals Charts.
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....